All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ins and outs of CAR T cells in the real word: Live Hub Event
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Here, we share a presentation by Ulrich Jӓger, Medical University of Vienna, Vienna, AT, on a case study to evaluate sequencing therapies for patients with high-risk diffuse large B cell lymphoma (DLBCL).
The Lymphoma Hub has previously covered sequencing therapies for patients with high risk DLBCL.
In this presentation, Jӓger shares a case study from 2019 of a 59-year-old female patient with DLBCL and the treatment decisions leading to chimeric antigen receptor (CAR) T-cell therapy, changes from 2019 to 2022 onwards in the algorithm for patients with DLBCL in clinical routine (Figure 1), and results in relapsed/refractory (R/R) patients with low-risk DLBCL treated with CAR T-cell therapy, presented at the European Hematology Association (EHA) 2023 Hydrid Congress (Figure 2).
Figure 1. Selection algorithm for patients with DLBCL in clinical routine: Austrian CAR T-cell Network*
*Adapted from Greinix, et al.1
Figure 2. Probability of OS and PFS of patients with R/R LBCL infused with commercial CAR T-cell compounds*
CAR, chimeric antigen receptor; CI, confidence interval; LBCL, large B-cell lymphoma; OS, overall survival; PFS, progression-free survival; R/R, relapsed/refractory
*Adapted from Rudzki, et al.2
†Data from 65 patients treated with axicabtagene ciloleucel or tisagenlecleucel.
Watch or download the presentation to learn more about the understanding of CAR T-cell therapy in patients with DLBCL, including:
This activity was supported through an educational grant from Bristol Myers Squibb.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
The ins and outs of CAR T cells in the real word: Live Hub Event
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox